Written Question·Department of Health and Social Care·UIN 69241
Rare Diseases: Drugs
Tabled: 21 July 2025
Answered: 1 September 2025
Question
Jim Shannon
Democratic Unionist Party — Strangford
To ask the Secretary of State for Health and Social Care, with reference to the NHS commercial framework for new medicines, updated on 29 January 2025, what assessment he has made of the potential impact of the requirement to provide value at or below the
Answer
Karin SmythIndication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 69241) →